T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

BACKGROUND: The current standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive (+) metastatic breast cancer is the combination of pertuzumab, trastuzumab and a taxane (P + T + taxane), while standard second-line is ado-trastuzumab-emtansine (T-DM1). The registratio...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ESMO Open
Auteurs principaux: Schettini, F., Conte, B., Buono, G., De Placido, P., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., De Laurentiis, M., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., De Placido, S., Giuliano, M., Arpino, G., Del Mastro, L.
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047485/
https://ncbi.nlm.nih.gov/pubmed/33819752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100099
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires